<DOC>
	<DOCNO>NCT01355718</DOCNO>
	<brief_summary>This trial conduct Asia . The primary objective study evaluate clinical safety profile 26 week NovoNorm® ( repaglinide ) insulin analogue combination therapy type 2 diabetes normal clinical practice condition Korea secondary objective evaluate safety efficacy 13 26 week NovoNorm® insulin analogue combination therapy type 2 diabetes normal clinical practice condition Korea .</brief_summary>
	<brief_title>Observational , Safety Study NovoNorm® ( Repaglinide ) Insulin Analogue Combination Therapy Type 2 Diabetes Korea</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<criteria>Informed consent obtain studyrelated activity . ( Studyrelated activity procedure relate recording data accord protocol . ) Patients type 2 diabetes mellitus Patients currently treat NovoNorm® alone combination metformin TZD Age : least 18 year old Patients prescribed insulin analogue addition current NovoNorm® ( with/without metformin/TZD ) treatment discretion Physician Known suspect allergy study product ( ) relate product Previous participation study . Participation define screened Patients treat insulin preparation ( include insulin analogue ) previously Females childbearing potential pregnant , breastfeed intend become pregnant use adequate contraceptive method ( adequate contraceptive measure require local law practice ) Patients unlikely comply protocol requirement , e.g . uncooperative attitude , inability return final visit Any disease condition Physician feel would interfere study participation evaluation result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>